- Home
- RSF vs ONCY Comparison
RSF vs ONCY Comparison
Compare RSF & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSF
- ONCY
- Stock Information
- Founded
- RSF 2016
- ONCY 1998
- Country
- RSF United States
- ONCY Canada
- Employees
- RSF N/A
- ONCY N/A
- Industry
- RSF Investment Managers
- ONCY Pharmaceuticals and Biotechnology
- Sector
- RSF Finance
- ONCY Health Care
- Exchange
- RSF Nasdaq
- ONCY Nasdaq
- Market Cap
- RSF 49.1M
- ONCY 49.1M
- IPO Year
- RSF N/A
- ONCY 1999
- Fundamental
- Price
- RSF $14.59
- ONCY $0.75
- Analyst Decision
- RSF
- ONCY Strong Buy
- Analyst Count
- RSF 0
- ONCY 4
- Target Price
- RSF N/A
- ONCY $4.33
- AVG Volume (30 Days)
- RSF 11.8K
- ONCY 1.2M
- Earning Date
- RSF 01-01-0001
- ONCY 07-31-2025
- Dividend Yield
- RSF 10.61%
- ONCY N/A
- EPS Growth
- RSF N/A
- ONCY N/A
- EPS
- RSF N/A
- ONCY N/A
- Revenue
- RSF N/A
- ONCY N/A
- Revenue This Year
- RSF N/A
- ONCY N/A
- Revenue Next Year
- RSF N/A
- ONCY N/A
- P/E Ratio
- RSF N/A
- ONCY N/A
- Revenue Growth
- RSF N/A
- ONCY N/A
- 52 Week Low
- RSF $14.81
- ONCY $0.33
- 52 Week High
- RSF $16.23
- ONCY $1.53
- Technical
- Relative Strength Index (RSI)
- RSF 37.70
- ONCY 68.49
- Support Level
- RSF $14.58
- ONCY $0.56
- Resistance Level
- RSF $14.73
- ONCY $0.81
- Average True Range (ATR)
- RSF 0.08
- ONCY 0.08
- MACD
- RSF -0.00
- ONCY 0.01
- Stochastic Oscillator
- RSF 20.00
- ONCY 80.78
About RSF RiverNorth Capital and Income Fund
RiverNorth Capital and Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income by investing in credit instruments, including a portfolio of securities of specialty finance and other financial companies.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.